These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3777780)

  • 21. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does protamine chloride neutralize low molecular weight heparin sufficiently?
    Gram J; Mercker S; Bruhn HD
    Thromb Res; 1988 Dec; 52(5):353-9. PubMed ID: 2851882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of heparin and protamine in presence of overdosage: in vitro study.
    Hanke AA; Severloh I; Flöricke F; Weber CF; Lang T
    Asian Cardiovasc Thorac Ann; 2021 Jan; 29(1):5-9. PubMed ID: 32854516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Action of heparin and protamine sulfate administration on serum complement levels in man].
    Di Perri T; Auteri A
    Boll Soc Ital Biol Sper; 1970 Oct; 46(20):817-9. PubMed ID: 5519564
    [No Abstract]   [Full Text] [Related]  

  • 25. Heparin rebound. Studies in patients and volunteers.
    Ellison N; Beatty CP; Blake DR; Wurzel HA; MacVaugh H
    J Thorac Cardiovasc Surg; 1974 May; 67(5):723-9. PubMed ID: 4823307
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative neutralization of lung- and mucosal-derived heparin by protamine sulfate using in vitro and in vivo methods.
    Lowary LR; Smith FA; Coyne E; Dunham NW
    J Pharm Sci; 1971 Apr; 60(4):638-40. PubMed ID: 5128383
    [No Abstract]   [Full Text] [Related]  

  • 27. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin-protamine does not aggravate local LPS-provoked leukocytic inflammation in vivo.
    Schramm R; Nickels RM; Harder Y; Langer F; Menger MD; Schäfers HJ
    Thorac Cardiovasc Surg; 2006 Dec; 54(8):506-11. PubMed ID: 17151963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiheparin properties of synthetic polycations].
    Dubovik VV; Etlis VS; Baluda VP; Sushkevich GN; Shevchuk AS
    Farmakol Toksikol; 1975; 38(2):193-8. PubMed ID: 1227887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Action of the heparin-protamine complex on serum complement. Research in vitro and in vivo].
    Di Perri T; Grossi A; Auteri A
    Boll Soc Ital Biol Sper; 1969 Aug; 45(16):1085-7. PubMed ID: 5374944
    [No Abstract]   [Full Text] [Related]  

  • 31. Body response to a second dose of heparin after heparin neutralization by protamine.
    Belko JS; Lerman SF
    J Cardiovasc Surg (Torino); 1966; 7(3):219-21. PubMed ID: 5938808
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin, protamine, and ionized calcium in vitro and in vivo.
    Goto H; Kushihashi T; Benson KT; Kato H; Fox DK; Arakawa K
    Anesth Analg; 1985 Nov; 64(11):1081-4. PubMed ID: 3931505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Modifications of coagulation after in-vivo meutralization of endogenous heparine liberated in dogs after injection of incompatible red blood cells].
    Dosne AM
    C R Seances Soc Biol Fil; 1971; 165(1):52-5. PubMed ID: 4257751
    [No Abstract]   [Full Text] [Related]  

  • 35. Experimental studies of heparin-protamine activity with special reference to protamine inhibition of clotting.
    ANDERSEN MN; MENDELOW M; ALFANO GA
    Surgery; 1959 Dec; 46():1060-8. PubMed ID: 13793331
    [No Abstract]   [Full Text] [Related]  

  • 36. Action of modified heparins on coagulation: in vitro and in vivo studies.
    Stemberger AW; Riedl A; Haas S; Breddin HK; Walenga JM; Blümel G
    Semin Thromb Hemost; 1991; 17 Suppl 1():80-4. PubMed ID: 1648792
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antagonistic effects of heparin and protamine sulfate on the electrophoretic mobility of blood platelets].
    Larcan A; Stoltz JF; Alexandre P
    Pathol Biol (Paris); 1969; 17(15):729-32. PubMed ID: 4907905
    [No Abstract]   [Full Text] [Related]  

  • 38. Persistent spontaneous heparinaemia in systemic mastocytosis.
    Nenci GG; Berrettini M; Parise P; Agnelli G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(3):453-63. PubMed ID: 6182065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. I. Effects of heparin fractions.
    Schmitz-Huebner U; Balleisen L; Asbeck F; van de Loo J
    Thromb Haemost; 1981 Oct; 46(3):612-6. PubMed ID: 7031982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.
    Bruins P; te Velthuis H; Eerenberg-Belmer AJ; Yazdanbakhsh AP; de Beaumont EM; Eijsman L; Trouwborst A; Hack CE
    Thromb Haemost; 2000 Aug; 84(2):237-43. PubMed ID: 10959695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.